文献速递贫血与红细胞疾病血栓与止血

抗-HBc血清学状态在原发免疫性血小板减少症中的意义

Significance of anti-HBc serological status in primary immune thrombocytopenia.
PubMed 文献 · Br J Haematol · 2021-12-01

研究分析725例原发免疫性血小板减少症(ITP)患者,探讨既往乙型肝炎病毒(HBV)暴露(HBsAg阴性、抗-HBc阳性)与疾病严重程度及治疗选择的关系,并整合一项前瞻性研究和两项回顾性研究评估抗-HBc状态对ITP特异性治疗反应及HBV再激活风险的影响。

要点

  • ITP患者中HBsAg阴性/抗-HBc阳性者占51.03%,阴性者占48.97%。
  • 与HBsAg阴性/抗-HBc阴性组相比,阳性组血小板计数更低、出血评分更高、住院时间更长。
  • HBsAg阴性/抗-HBc阳性组初始完全缓解率低于阴性组(45.2% vs 59.8%,P=0.027)。

核心结论

  • 既往HBV暴露与ITP患者疾病严重程度和住院相关。
  • 抗-HBc阳性可考虑作为ITP特异性治疗反应不佳的预测因素。

研究设计与样本

  • 分析725例诊断为ITP患者的数据,以阐明抗-HBc血清学状态与疾病严重程度的关联。
  • 整合一项已发表的前瞻性研究(大剂量地塞米松,大剂量地塞米松联合重组人血小板生成素,NCT01734044)和两项回顾性研究(标准剂量和低剂量利妥昔单抗)的数据,评估抗-HBc血清学状态对ITP特异性治疗反应和结局的影响,以及这些治疗相关的HBV再激活风险。

主要发现

  • ITP患者中HBsAg阴性/抗-HBc阳性者占51.03%,HBsAg阴性/抗-HBc阴性者占48.97%。
  • 与HBsAg阴性/抗-HBc阴性组相比,HBsAg阴性/抗-HBc阳性组血小板计数更低、出血评分更高、住院时间更长(P分别为0.002、0.033和0.008)。
  • HBsAg阴性/抗-HBc阳性组初始完全缓解率低于HBsAg阴性/抗-HBc阴性组(45.2% vs 59.8%,P=0.027)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The association of previous hepatitis B virus (HBV) exposure [hepatitis B surface antigen (HBsAg) negative, hepatitis B core antibody (anti-HBc/HBcAb) positive] with disease severity and decision on treatment option in primary immune thrombocytopenia (ITP) patients remains unclear. Data from 725 patients diagnosed with ITP were analyzed to elucidate the association between anti-HBc serological status and disease severity. Data from a published prospective study [high-dose dexamethasone (HD-DXM), HD-DXM plus recombinant human thrombopoietin, NCT01734044] and two retrospective studies (standard-dose and low-dose rituximab) were rearranged to evaluate the impact of anti-HBc serological status on the response and outcome to ITP-specific treatments and the risk of HBV reactivation related to these treatments. The prevalence of HBsAg- HBcAb+ and HBsAg- HBcAb- in ITP patients was 51·03% and 48·97% respectively. Compared to the HBsAg- HBcAb- group, patients in the HBsAg- HBcAb+ group had lower platelet count, higher bleeding score, and longer hospitalization (P = 0·002, 0·033, and 0·008 respectively). Moreover, the initial complete response rate of HBsAg- HBcAb+ patients was lower than that of HBsAg- HBcAb- patients (45·2% vs 59·8%, P = 0·027). In conclusion, previous HBV exposure was correlated with disease severity and hospitalization in ITP patients. Anti-HBc positivity may be considered as a predictor for poor response to ITP-specific treatments.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Wang L, Li L, Li C, et al. Significance of anti-HBc serological status in primary immune thrombocytopenia. Br J Haematol. 2021. PMID: 34854079. doi:10.1111/bjh.17977

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。